AMPH vs EOLS
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.
Side-by-side fundamentals
| Metric | AMPH | EOLS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.30 | $5.89 | |
| Market cap as of 2026-07-23 | $864M | $379M | |
| P/E as of 2026-07-23 | 10.90 | n/a | |
| PEG as of 2026-07-23 | -1.77 | n/a | |
| Net margin as of 2026-07-23 | +11.0% | -14.4% | AMPH higher |
| Gross margin as of 2026-07-23 | +47.3% | +66.1% | EOLS higher |
| Operating margin as of 2026-07-23 | +16.2% | -8.1% | AMPH higher |
| ROE as of 2026-07-23 | +10.2% | -410.2% | AMPH higher |
| ROA as of 2026-07-23 | +4.8% | -19.4% | AMPH higher |
| Debt / equity as of 2026-07-23 | 0.79 | 22.00 | AMPH lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.4% | +9.6% | EOLS higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +26.0% | EOLS higher |
| Beta as of 2026-07-23 | 0.91 | 1.39 | |
| 1-year return as of 2026-07-22 close | -7.6% | -37.0% | AMPH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.